

As of January 8, 2024, using [Lexis Advance](#), the relevant cites of Amgen that also cite *Wands* are:

1. *Ex parte Pen*, 2023 Pat. App. LEXIS 1857 at *5;
2. *Pelican Biothermal v. Va-Q-Tec AG*, 2023 Pat. App. LEXIS 1936 at *17–18, 46;
3. *Gillette Co., LLC v. Sphere USA, LLC*, 2023 Pat. App. LEXIS 3126 at *46, 50–52, 58;
4. [*ESCO Grp. LLC v. Deere & Co.*](#), 2023 U.S. Dist. LEXIS 110633 at *54 (D.Del. June 22, 2023);
5. [*Orexo AB v. Sun Pharm. Indus.*](#), 2023 U.S. Dist. LEXIS 120114 at *69–71 (D.N.J. June 30, 2023);
6. [*In re Entresto Sacubitril/Valsartan Patent Litig.*](#), 2023 U.S. Dist. LEXIS 117240 at *51–52 (D.Del. July 7, 2023);
7. [*MHL Custom, Inc. v. Waydoo USA, Inc.*](#), 2023 U.S. Dist. LEXIS 157220 at *13 (D.Del. Sept. 6, 2023);
8. [*Teva Pharms. Int’l GMBH v. Eli Lilly & Co.*](#), 2023 U.S. Dist. LEXIS 171953 at *61–62 (D.Mass. Sept. 26, 2023);
9. [*Allergan USA, Inc. v. MSN Labs. Priv. Ltd.*](#), 2023 U.S. Dist. LEXIS 172641 at *8–9 (D.Del. Sept. 27, 2023);
10. [*Oyster Optics, LLC v. Ciena Corp.*](#), 2023 U.S. Dist. LEXIS 190950 at *15 (N.D.Cal. Oct. 24, 2023);
11. [*In re Starrett*](#), 2023 U.S. App. LEXIS 14231 at *5–6, 10, 12, 2023 U.S.P.Q.2d (BNA) 684 (Fed. Cir. June 8, 2023);
12. [*Medytox, Inc. v. Galderma SA*](#), 71 F.4th 990, 995–96, 998 (Fed. Cir. June 27, 2023); and
13. [*Baxalta, Inc. v. Genentech, Inc.*](#), 81 F.4th 1362, 1366 (Fed. Cir. Sept. 20, 2023).